Penpulimab Regimens May Improve Outcomes in Resectable NSCLC
Emerging combination therapy using penpulimab, anlotinib, and chemotherapy shows promise for improving pathological response and survival outcomes in resectable non-small cell lung cancer.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.